Companies: 10,795·Total market cap: $144.5T
Big Pharma Split Corp.

Big Pharma Split Corp.

PRM.TOTSXFinancial Services● Active
$13.75
+$0.12(+0.88%)
Market Cap$17933259
P/E Ratio—
52W High$15.5
52W Low$10.71
Free Cash FlowFinancialsRevenue

Big Pharma Split Corp. (PRM.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PRM.TO · free cash flow · updated Jun 9, 2026

Core FCF metrics

Free cash flow was −$1.1M for FY2025 (fiscal year ending 2025-12-31), up 18.6% year-over-year The FCF margin was -72.6%.

FY2025 Free Cash Flow−$1.1M▲ +18.6% YoY
Trailing 12M (TTM)−$1.3Mtrailing 4 quarters sum
FCF Margin-72.6%−$1.1M ÷ revenue
3-Year CAGRN/AN/A — contains negative FCF
5-Year CAGRN/AN/A — contains negative FCF
FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

Positive FCFNegative FCF
Free Cash Flow
YoY Growth %
prm.to free cash flow history · prm.to free cash flow chart · prm.to free cash flow growth rate · prm.to free cash flow last 10 years

Annual free cash flow data

Fiscal YearFree Cash FlowYoY ChangeFCF Margin
FY2025Latest−$1.1M▲ +18.6%-72.6%
FY2024−$1.3M▼ 110.9%-70.1%
FY2023$11.9M▲ +950.9%—
FY2022$1.1M▲ +112.5%28.7%
FY2021−$9.0M▼ 307.0%-167.9%
FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP
prm.to free cash flow 2025 · prm.to free cash flow 2024 · prm.to free cash flow 2023 · prm.to operating cash flow

FCF valuation metrics

Big Pharma Split Corp. (PRM.TO) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)
N/A
Free Cash Flow ÷ Market Cap
per FMP freeCashFlowYieldTTM definition
FCF per Share (TTM)
N/A
TTM FCF ÷ Shares Outstanding
Price / FCF
N/A
Share Price ÷ FCF per Share
EV / FCF (TTM)
N/A
Enterprise Value basis
!

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31
prm.to price to free cash flow · prm.to free cash flow yield · prm.to free cash flow per share · prm.to price to cash flow ratio

Cash flow statement summary

For FY2025, Big Pharma Split Corp. generated −$1.1M in operating cash flow and spent 0M in capital expenditures, yielding −$1.1M in free cash flow.

Operating Activities
−$1.1M
Cash from core business operations
2025-12-31
Investing Activities
+$0.0M
CapEx, acquisitions & investments
2025-12-31
Financing Activities
+$1.8M
Buybacks, dividends & debt
2025-12-31
FCF FormulaOperating CF (−$1.1M) − |CapEx| (0M) = FCF (−$1.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →
prm.to cash flow statement · prm.to cash flow statement 2025 · prm.to operating cash flow · prm.to cash flow from operations

Free cash flow vs peers (Financial Services)

#CompanyFree Cash FlowYoY
#1
Big Pharma Split Corp.
Big Pharma Split Corp.YOU
PRM.TO
−$1.1M+18.6%
#2
JPMorgan Chase & Co.
JPMorgan Chase & Co.
JPM
$100.87B+340.1%#3
Berkshire Hathaway Inc.
Berkshire Hathaway Inc.
BRK-B
$25.04B+115.6%#4
Berkshire Hathaway Inc.
Berkshire Hathaway Inc.
BRK-A
$25.04B+115.6%#5
Visa Inc.
Visa Inc.
V
$21.58B+15.4%#6
Mastercard Incorporated
Mastercard Incorporated
MA
$16.91B+18.2%
Financial Services · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Big Pharma Split Corp. (PRM.TO) reported free cash flow of −$1.1M for FY2025 (fiscal year ending 2025-12-31), up 18.6% year-over-year. The FCF margin was -72.6%.

Based on available data, Big Pharma Split Corp. has maintained positive free cash flow for at least 5 fiscal year(s). FCF peaked at $11.9M in FY2023.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.
RevenueFinancial statementsNet incomeEarningsForecastPrice historyMarket capCash on handP/E ratio

Frequently asked questions

PRM.TO free cash flow · 8 questions

Big Pharma Split Corp. free cash flow was −$1.1M for FY2025, up 18.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.3M.

PRM.TO free cash flowPRM.TO FCFPRM.TO FCF 2025PRM.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Big Pharma Split Corp. · Big Pharma Split Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026